GAMMA Investing LLC Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 31.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,173 shares of the company’s stock after purchasing an additional 768 shares during the quarter. GAMMA Investing LLC’s holdings in Moderna were worth $132,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. raised its position in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after buying an additional 15,218 shares during the last quarter. Inspire Trust Co. N.A. raised its holdings in shares of Moderna by 73.5% during the third quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock worth $1,104,000 after purchasing an additional 7,000 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in Moderna by 1.4% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock valued at $19,239,000 after purchasing an additional 3,978 shares during the period. Toronto Dominion Bank boosted its holdings in Moderna by 23.7% in the third quarter. Toronto Dominion Bank now owns 131,477 shares of the company’s stock valued at $8,787,000 after purchasing an additional 25,177 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $43.17 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The firm has a market capitalization of $16.61 billion, a PE ratio of -7.42 and a beta of 1.60. The business’s 50 day moving average price is $42.99 and its 200-day moving average price is $70.69.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.39) EPS. As a group, equities research analysts expect that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MRNA shares. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Piper Sandler reissued an “overweight” rating and issued a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Wolfe Research initiated coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. UBS Group decreased their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Leerink Partners lowered their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $78.83.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.